Orchestra BioMed Holdings Inc Financials
Orchestra BioMed Holdings Inc (OBIO) reported $32.0M in revenue over the twelve months to Jun 30, 2026, up 986.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending and external funding, rather than gross-margin economics, define how this business currently operates.
The 2025 gross margin of99.4% alongside an operating margin of-154.7% shows that direct production costs are not the constraint; development and overhead costs consume far more than gross profit.
Revenue reached
Net loss of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Orchestra BioMed Holdings Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Orchestra BioMed Holdings Inc scores -0.98, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($316.2M) relative to total liabilities ($51.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Orchestra BioMed Holdings Inc passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Orchestra BioMed Holdings Inc reported a net loss of $52.7M while operations used $49.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Orchestra BioMed Holdings Inc generated $33.5M in revenue in fiscal year 2025. This represents an increase of 1169.2% from the prior year.
Orchestra BioMed Holdings Inc's EBITDA was -$51.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.6% from the prior year.
Orchestra BioMed Holdings Inc reported -$52.7M in net income in fiscal year 2025. This represents an increase of 13.6% from the prior year.
Orchestra BioMed Holdings Inc earned -$1.11 per diluted share (EPS) in fiscal year 2025. This represents an increase of 33.1% from the prior year.
Cash & Balance Sheet
Orchestra BioMed Holdings Inc recorded an outflow of $49.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 2.7% from the prior year.
Orchestra BioMed Holdings Inc held $34.7M in cash against $15.0M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Orchestra BioMed Holdings Inc's gross margin was 99.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 7.2 percentage points from the prior year.
Orchestra BioMed Holdings Inc's ROE was -98.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 86.8 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Orchestra BioMed Holdings Inc invested $58.2M in research and development in fiscal year 2025. This represents an increase of 35.9% from the prior year.
Orchestra BioMed Holdings Inc invested $489K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 69.2% from the prior year.
Not reported for fiscal year 2025.
OBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $88K-20.0% | $110K-99.6% | $30.9M+3490.8% | $861K+3.0% | $836K-3.7% | $868K+243.1% | $253K-74.4% | $987K |
| Cost of Revenue | $25K-21.9% | $32K-37.3% | $51K+4.1% | $49K+6.5% | $46K+4.5% | $44K-24.1% | $58K-14.7% | $68K |
| Gross Profit | $63K-19.2% | $78K-99.7% | $30.9M+3701.2% | $812K+2.8% | $790K-4.1% | $824K+322.6% | $195K-78.8% | $919K |
| R&D Expenses | $16.6M+5.1% | $15.8M-6.2% | $16.8M+19.9% | $14.0M+1.3% | $13.9M+2.8% | $13.5M+22.9% | $11.0M-5.4% | $11.6M |
| SG&A Expenses | $5.8M-8.5% | $6.4M-12.6% | $7.3M+2.7% | $7.1M+13.3% | $6.3M0.0% | $6.3M+6.1% | $5.9M+4.1% | $5.7M |
| Operating Income | -$22.4M-1.3% | -$22.1M-426.9% | $6.8M+133.2% | -$20.3M-5.1% | -$19.3M-2.1% | -$18.9M-13.5% | -$16.7M-2.0% | -$16.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $297K | $0 |
| Net Income | -$23.8M-14.8% | -$20.7M-431.3% | $6.2M+130.0% | -$20.8M-7.6% | -$19.4M-3.2% | -$18.8M-16.1% | -$16.2M-4.7% | -$15.4M |
| EPS (Diluted) | -$0.38-15.2% | -$0.33 | $0.26 | -$0.40+20.0% | -$0.50-2.0% | -$0.49-14.0% | -$0.43-4.9% | -$0.41 |
Not reported in any period shown, so not listed: Income Tax.
OBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $115.7M+14.9% | $100.7M-12.4% | $114.9M+9.6% | $104.8M+144.7% | $42.8M-27.5% | $59.1M-22.5% | $76.2M+1.1% | $75.3M |
| Current Assets | $111.2M+15.6% | $96.2M-10.8% | $107.9M+10.4% | $97.8M+172.5% | $35.9M-30.9% | $51.9M-25.0% | $69.2M+0.9% | $68.6M |
| Cash & Equivalents | $20.5M-27.8% | $28.4M-18.2% | $34.7M-17.4% | $42.0M+124.1% | $18.7M+2.2% | $18.3M-17.6% | $22.3M-13.1% | $25.6M |
| Inventory | $250K-9.7% | $277K-10.6% | $310K-15.1% | $365K+97.3% | $185K+37.0% | $135K-22.0% | $173K-26.1% | $234K |
| Accounts Receivable | $51K-39.3% | $84K-11.6% | $95K+82.7% | $52K-37.3% | $83K-6.7% | $89K-3.3% | $92K-20.0% | $115K |
| Total Liabilities | $86.3M+73.6% | $49.7M-3.5% | $51.5M-15.7% | $61.1M+43.6% | $42.5M+0.8% | $42.2M-2.4% | $43.2M+48.5% | $29.1M |
| Current Liabilities | $13.5M-1.6% | $13.7M-18.2% | $16.7M-19.0% | $20.7M+21.1% | $17.1M+10.1% | $15.5M-4.4% | $16.2M-0.1% | $16.2M |
| Long-Term Debt | N/A | $15.0M0.0% | $15.0M0.0% | $15.0M0.0% | $15.0M0.0% | $15.0M0.0% | $15.0M | N/A |
| Total Equity | $19.3M-53.1% | $41.2M-23.1% | $53.6M+22.5% | $43.7M+14726.8% | $295K-98.2% | $16.9M-48.9% | $33.0M-28.7% | $46.2M |
| Retained Earnings | -$407.0M-6.2% | -$383.3M-5.7% | -$362.6M+1.7% | -$368.8M-6.0% | -$348.0M-5.9% | -$328.6M-6.1% | -$309.9M-5.5% | -$293.7M |
Not reported in any period shown, so not listed: Goodwill.
OBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.3M+12.8% | -$22.2M-876.6% | -$2.3M+84.4% | -$14.6M+6.3% | -$15.5M+6.6% | -$16.6M-22.7% | -$13.5M+1.2% | -$13.7M |
| Capital Expenditures | $254K+38.0% | $184K+457.6% | $33K-89.4% | $310K+811.8% | $34K-69.6% | $112K+5.7% | $106K+55.9% | $68K |
| Free Cash Flow | -$19.6M+12.4% | -$22.4M-870.6% | -$2.3M+84.5% | -$14.9M+4.5% | -$15.6M+7.0% | -$16.7M-22.6% | -$13.6M+0.9% | -$13.8M |
| Investing Cash Flow | -$23.3M-325.9% | $10.3M+158.3% | -$17.7M+54.1% | -$38.6M-335.9% | $16.4M+25.8% | $13.0M+446.4% | -$3.8M-773.8% | $557K |
| Financing Cash Flow | $34.7M+528.7% | $5.5M-56.3% | $12.7M-83.4% | $76.4M+17949.8% | -$428K-44.6% | -$296K-102.1% | $13.9M-7.2% | $15.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
OBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.6%+0.7pp | 70.9%-28.9pp | 99.8%+5.5pp | 94.3%-0.2pp | 94.5%-0.4pp | 94.9%+17.8pp | 77.1%-16.0pp | 93.1% |
| Operating Margin | -25404.5% | -20069.1% | 21.9% | -2359.2% | -2311.8% | -2179.8% | -6591.7% | -1655.7% |
| Net Margin | -26994.3% | -18810.0% | 20.2% | -2419.1% | -2316.2% | -2160.7% | -6385.4% | -1562.9% |
| Return on Equity | -122.9%-72.7pp | -50.2%-61.9pp | 11.7%+59.3pp | -47.6%+6516.1pp | -6563.7%-6452.5pp | -111.3%-62.2pp | -49.0%-15.6pp | -33.4% |
| Return on Assets | -20.5%0.0pp | -20.6%-26.0pp | 5.4%+25.3pp | -19.9%+25.3pp | -45.2%-13.5pp | -31.8%-10.5pp | -21.2%-0.7pp | -20.5% |
| Current Ratio | 8.26+1.2x | 7.03+0.6x | 6.45+1.7x | 4.73+2.6x | 2.10-1.2x | 3.35-0.9x | 4.270.0x | 4.23 |
| Debt-to-Equity | 4.47+4.1x | 0.36+0.1x | 0.28-0.1x | 0.34-50.5x | 50.85+50.0x | 0.89+0.4x | 0.46-0.2x | 0.63 |
| FCF Margin | -22256.8% | -20320.0% | -7.4% | -1725.9% | -1861.4% | -1927.2% | -5392.9% | -1394.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Orchestra BioMed Holdings Inc Ranks
Frequently Asked Questions
What is Orchestra BioMed Holdings Inc's annual revenue?
Orchestra BioMed Holdings Inc (OBIO) reported $33.5M in total revenue for fiscal year 2025. This represents a 1169.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Orchestra BioMed Holdings Inc's revenue growing?
Orchestra BioMed Holdings Inc (OBIO) revenue grew by 1169.2% year-over-year, from $2.6M to $33.5M in fiscal year 2025.
Is Orchestra BioMed Holdings Inc profitable?
No, Orchestra BioMed Holdings Inc (OBIO) reported a net income of -$52.7M in fiscal year 2025.
What is Orchestra BioMed Holdings Inc's EBITDA?
Orchestra BioMed Holdings Inc (OBIO) had EBITDA of -$51.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Orchestra BioMed Holdings Inc have?
As of fiscal year 2025, Orchestra BioMed Holdings Inc (OBIO) had $34.7M in cash and equivalents against $15.0M in long-term debt.
What is Orchestra BioMed Holdings Inc's gross margin?
Orchestra BioMed Holdings Inc (OBIO) had a gross margin of 99.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Orchestra BioMed Holdings Inc's return on equity (ROE)?
Orchestra BioMed Holdings Inc (OBIO) has a return on equity of -98.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Orchestra BioMed Holdings Inc's free cash flow?
Orchestra BioMed Holdings Inc (OBIO) recorded an outflow of $49.5M in free cash flow during fiscal year 2025. This represents a 2.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Orchestra BioMed Holdings Inc's operating cash flow?
Orchestra BioMed Holdings Inc (OBIO) recorded an outflow of $49.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Orchestra BioMed Holdings Inc's total assets?
Orchestra BioMed Holdings Inc (OBIO) had $114.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Orchestra BioMed Holdings Inc's capital expenditures?
Orchestra BioMed Holdings Inc (OBIO) invested $489K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Orchestra BioMed Holdings Inc spend on research and development?
Orchestra BioMed Holdings Inc (OBIO) invested $58.2M in research and development during fiscal year 2025.
What is Orchestra BioMed Holdings Inc's current ratio?
Orchestra BioMed Holdings Inc (OBIO) had a current ratio of 6.45 as of fiscal year 2025, which is generally considered healthy.
What is Orchestra BioMed Holdings Inc's debt-to-equity ratio?
Orchestra BioMed Holdings Inc (OBIO) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Orchestra BioMed Holdings Inc's return on assets (ROA)?
Orchestra BioMed Holdings Inc (OBIO) had a return on assets of -45.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Orchestra BioMed Holdings Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Orchestra BioMed Holdings Inc (OBIO) held $111.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $49.0M over that year. Dividing the one by the other, the reported balance equals about 27 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Orchestra BioMed Holdings Inc's Altman Z-Score?
Orchestra BioMed Holdings Inc (OBIO) has an Altman Z-Score of -0.98, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Orchestra BioMed Holdings Inc's Piotroski F-Score?
Orchestra BioMed Holdings Inc (OBIO) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Orchestra BioMed Holdings Inc's earnings high quality?
Orchestra BioMed Holdings Inc (OBIO) reported a net loss of $52.7M while operations used $49.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Orchestra BioMed Holdings Inc?
Orchestra BioMed Holdings Inc (OBIO) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.